- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
54
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
54 companies
Madrigal Pharmaceuticals
Market Cap: US$13.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$571.44
7D
0.5%
1Y
83.7%
Arcutis Biotherapeutics
Market Cap: US$3.6b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$29.02
7D
-6.5%
1Y
113.9%
Caris Life Sciences
Market Cap: US$7.6b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$26.76
7D
-5.6%
1Y
n/a
Marker Therapeutics
Market Cap: US$24.5m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.47
7D
3.5%
1Y
-64.4%
Mereo BioPharma Group
Market Cap: US$345.3m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$2.17
7D
1.9%
1Y
-37.1%
Legend Biotech
Market Cap: US$4.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$22.32
7D
-14.5%
1Y
-32.4%
RenovoRx
Market Cap: US$35.2m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.96
7D
1.9%
1Y
-23.2%
ARS Pharmaceuticals
Market Cap: US$1.0b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.24
7D
2.4%
1Y
-13.8%
Soleno Therapeutics
Market Cap: US$2.8b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$52.00
7D
1.6%
1Y
8.5%
Achieve Life Sciences
Market Cap: US$247.0m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.64
7D
-1.1%
1Y
12.3%
Lineage Cell Therapeutics
Market Cap: US$402.3m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.66
7D
-1.8%
1Y
232.0%
Capricor Therapeutics
Market Cap: US$1.3b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$26.02
7D
-8.9%
1Y
87.5%
Aldeyra Therapeutics
Market Cap: US$273.1m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$4.54
7D
-8.3%
1Y
-10.3%
Pelthos Therapeutics
Market Cap: US$71.0m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$22.99
7D
-15.3%
1Y
288.9%
AC Immune
Market Cap: US$311.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.15
7D
13.3%
1Y
7.9%
Longeveron
Market Cap: US$13.0m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.61
7D
2.7%
1Y
-66.5%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$20.37
7D
2.0%
1Y
47.7%
Viridian Therapeutics
Market Cap: US$3.1b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$32.31
7D
1.3%
1Y
50.0%
Precigen
Market Cap: US$1.3b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$3.69
7D
0%
1Y
447.8%
Altimmune
Market Cap: US$549.9m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$5.27
7D
-6.1%
1Y
-41.4%
Insmed
Market Cap: US$42.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$197.01
7D
0.2%
1Y
168.4%
Vera Therapeutics
Market Cap: US$3.5b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$49.80
7D
10.6%
1Y
13.3%
Invivyd
Market Cap: US$540.8m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$2.32
7D
-2.5%
1Y
415.0%
BioRestorative Therapies
Market Cap: US$9.9m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.11
7D
2.8%
1Y
-24.0%
Praxis Precision Medicines
Market Cap: US$6.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$268.80
7D
-0.8%
1Y
271.4%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.21
7D
5.6%
1Y
15.2%
Unicycive Therapeutics
Market Cap: US$133.9m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.23
7D
-5.3%
1Y
-11.0%
Roivant Sciences
Market Cap: US$15.4b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$22.10
7D
5.3%
1Y
82.6%
SELLAS Life Sciences Group
Market Cap: US$289.2m
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$2.03
7D
11.5%
1Y
120.6%
Rhythm Pharmaceuticals
Market Cap: US$7.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$113.56
7D
8.0%
1Y
105.5%
Zymeworks
Market Cap: US$1.9b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$25.48
7D
-3.5%
1Y
85.0%
Day One Biopharmaceuticals
Market Cap: US$858.4m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$8.36
7D
-3.2%
1Y
-33.8%
Ionis Pharmaceuticals
Market Cap: US$13.1b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$80.82
7D
-0.8%
1Y
112.1%
Prelude Therapeutics
Market Cap: US$140.9m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.71
7D
17.1%
1Y
90.9%
Creative Medical Technology Holdings
Market Cap: US$7.9m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$2.15
7D
-3.2%
1Y
-8.2%
Savara
Market Cap: US$1.7b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$6.92
7D
7.0%
1Y
112.3%